Document Detail

Comparison of UW versus HTK solution for myocardial protection in heart transplantation.
MedLine Citation:
PMID:  11271286     Owner:  NLM     Status:  MEDLINE    
In order to evaluate the protective effect of University of Wisconsin (UW) solution in heart transplantation, a retrospective comparative study with histidine-tryptophane-ketoglutarate (HTK) solution was initiated. In group I, we included 160 patients with HTK preservation, while group II consisted of 50 patients who had their transplant protected with UW solution. All patients received standard quadruple drug therapy for immunosuppression. The average ischaemic time of the donor hearts in group I was 142+/-44 min, ranging from 83 to 235 min. Acute immediate perioperative graft failure occurred in six cases (3.8%). Statistical analysis including the chi-square test, revealed a significant increase in the incidence of acute perioperative graft failure when compared with duration of ischaemic time (P < 0.01). Within the first 30 postoperative days, 24 patients died (15% early mortality). The same statistical correlation was evident between the incidence of early mortality and duration of graft ischaemic time. The 30-day and 6-month survival rates were 81% and 78%, respectively. The average ischemic time of the donor hearts in group II was 193+/-50 min ranging from 100 to 360 min, which was significantly longer in comparison with the group I (P < 0.05). Acute perioperative graft failure occurred once (2%); the patient was retransplanted successfully. Five patients died within the first 30 postoperative days (10% early mortality). There was no correlation between length of ischaemic time and incidence of acute graft failure or early mortality. The 30-day and 6-month survival rates were 90% and 88%, respectively and, thus, better when compared with group I. In both groups similar results were achieved with regard to postoperative NYHA status of the patients and incidence of cardiac arrhythmias. Myocardial preservation with HTK solution showed satisfying results as long as the ischaemic time did not exceed 4 h. The early functional results achieved with UW graft protection were excellent, even with ischaemic times longer than 4 h and not depending on lenght of ischaemic period.
H Reichenspurner; C Russ; F Wagner; P Uberfuhr; G Nollert; C Weinhold; B Reichart
Related Documents :
7769736 - Surgical management of infrainguinal arterial prosthetic graft infections: review of a ...
24174726 - Evaluation of the effect of one stage versus two stage full mouth disinfection on c-rea...
11287506 - Thrombolysis of clotted hemodialysis grafts with tissue-type plasminogen activator.
23388226 - Effects of two different treatments with continuous renal replacement therapy in patien...
14571746 - Simple closure of chronic duodenal ulcer perforation in the era of helicobacter pylori:...
22445916 - Assessment of articular cartilage repair tissue after matrix-associated autologous chon...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Transplant international : official journal of the European Society for Organ Transplantation     Volume:  7 Suppl 1     ISSN:  0934-0874     ISO Abbreviation:  Transpl. Int.     Publication Date:  1994  
Date Detail:
Created Date:  2001-02-22     Completed Date:  2001-04-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8908516     Medline TA:  Transpl Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  S481-4     Citation Subset:  IM    
Department of Cardiac Surgery, University Hospital Grosshadern, München, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arrhythmias, Cardiac / epidemiology
Chi-Square Distribution
Graft Survival*
Heart Transplantation / mortality,  physiology*,  statistics & numerical data
Middle Aged
Organ Preservation Solutions*
Postoperative Complications / epidemiology
Postoperative Period
Potassium Chloride*
Retrospective Studies
Survival Rate
Time Factors
Treatment Failure
Reg. No./Substance:
0/Bretschneider cardioplegic solution; 0/Organ Preservation Solutions; 0/University of Wisconsin-lactobionate solution; 11061-68-0/Insulin; 315-30-0/Allopurinol; 50-99-7/Glucose; 512-69-6/Raffinose; 58-61-7/Adenosine; 59-46-1/Procaine; 69-65-8/Mannitol; 70-18-8/Glutathione; 7447-40-7/Potassium Chloride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A report of the eurotransplant randomized multicenter study comparing kidney graft preservation with...
Next Document:  Successful cardiac presrevation for 12 hours using nondepolarizing cold cardioplegia. A canine model...